Borderline Resectable Hepatocellular Carcinoma
1 clinical trials · Condition
◉ Watch Borderline Resectable Hepatocellular Carcinoma
| Record | Firm | Date |
|---|---|---|
| The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC (NCT05042336) | Sichuan University | 2021-09-01 |
Track Borderline Resectable Hepatocellular Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.